Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTR1E | P28566 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071813 | 0.98 | IDO1 (0.49) | IDO1LMNAMEN1KMT2AHTR1E | |
| SCHEMBL7115970 | 0.92 | IDO1 (0.44) | IDO1LMNAMEN1KMT2AHTR1E | |
| SCHEMBL961019 | 0.80 | SLC6A3 (0.57) | IDO1LMNAMEN1KMT2AHTR1E | |
| SCHEMBL8910008 | 0.79 | CYP19A1 (0.42) | MAPTGAAL3MBTL1EPHX1KDM4E | |
| SCHEMBL13124077 | 0.78 | SLC6A3 (0.58) | IDO1LMNAMEN1KMT2AHTR1E | |
| SCHEMBL959762 | 0.78 | SLC6A3 (0.58) | IDO1LMNAMEN1KMT2AHTR1E | |
| SCHEMBL8909681 | 0.78 | CYP11B2 (0.44) | MAPTKDM4ECYP3A4CYP2C19 | |
| SCHEMBL961750 | 0.76 | SLC6A3 (0.53) | IDO1LMNAMEN1KMT2AHTR1E | |
| SCHEMBL28135586 | 0.73 | IDO1 (0.47) | IDO1LMNAMEN1KMT2AHTR1E | |
| SCHEMBL522585 | 0.72 | IDO1 (0.50) | IDO1LMNAMEN1KMT2AHTR1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | NOVO NORDISK A/S (DK) | 2011-12-29 | — | — | US | disclosed |
| EP-2346892-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | Novo Nordisk A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010055136-A1 | PROCESS FOR THE PURIFICATION OF ANTIBODIES USING AFFINITY RESINS COMPRISING SPECIFIC LIGANDS | NOVO NORDISK A/S (DK) | 2010-05-20 | — | — | WO | disclosed |
| US-7071168-B2 | Anti-cancer compounds and methods related thereto | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2006-07-04 | — | — | US | disclosed |
| CN-1370526-A | Treating method of nuclear factor-KB mediated diseases and dysfuction | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | disclosed |
| US-6388054-B1 | AMINO ACID SEQUENCES OF ANTITUMOR AGENTS AND APOPTOSIS AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-14 | — | — | US | disclosed |
| WO-2000011022-A1 | ANTI-CANCER COMPOUNDS AND METHODS RELATED THERETO | STEWART JOHN M (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319592-A1 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands | FCGR1A, FCGR2A, FCGR3B | IDO1 3886/4885LMNA 4496/4885MEN1 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.